Due to the near perfect conservation of CDK9 and CDK7 between human and mouse, we were able to engineer these mutations in murine B-cell acute lymphoblastic leukemia (B-ALL) cells driven by the BCR-ABL oncogene in a homozygous Arf null background (83). The gene discussed is ABL1; the disease is B-cell acute lymphoblastic leukemia.